Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of August 2006, with the report dated August 15, 2006. The filing serves to incorporate by reference a press release issued on August 14, 2006, regarding a specific legal development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a legal event rather than a financial performance statement.
Material Changes
The material change disclosed is the filing of a motion for a preliminary injunction in a patent infringement case involving the company's product Plavix.
Outlook, Risks, and Contingencies
- Legal Contingency: Sanofi-Aventis has initiated legal action seeking a preliminary injunction in a Plavix patent infringement case.
- Risk Factor: The outcome of this litigation could impact the company's intellectual property rights and market exclusivity for Plavix.
Investor Verification Checklist
- Verify the status and details of the preliminary injunction motion filed in the Plavix patent infringement case.
- Review the full text of the press release (Exhibit 99.1) for specific allegations and opposing parties.
- Assess the potential financial impact of the litigation on future Plavix revenue streams.